Phase IV Studies Encounter Delays, Yield Mixed Data – Tufts Report
Executive Summary
A survey of 61 post-marketing drug studies conducted by the Tufts Center for the Study of Drug Development concluded that almost half of those trials did not meet their projected completion date. The center released results of the report, which appears in the May/June Tufts CSDD Impact Report, May 15
You may also be interested in...
FDA Reform Bill Leaves Senate With Reduced Safety Powers But Stiffer Fines
Legislation to reauthorize FDA's user fee program and expand the agency's oversight powers on drug safety has cleared the Senate with much stronger fines than originally envisioned by the sponsors, thanks to an amendment by Sen. Charles Grassley, R-Iowa
PDUFA III Authorizes FDA To Alert MDs To Failed Phase IV Commitments
FDA will have the authority to require manufacturers to inform prescribers if they fail to complete Phase IV commitments under the Prescription Drug User Fee Act reauthorization
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.